Octoplus« Terug naar discussie overzicht

1. [verwijderd] 22 oktober 2009 11:37

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   WEB SEMINARS
   OctoPlus conducts web seminars to share our technical and scientific knowledge in formulation development and drug delivery. Click on the links below to view or participate in our web seminars:
   
   Web seminar June 2009: Liposomes for drug delivery
   
   Web seminar October 2009: Hydrogels for controlled delivery of protein therapeutics
   
2. [verwijderd] 23 oktober 2009 07:03

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   October 23, 2009
   
   PHARMACEUTICAL INNOVATORS
   OctoPlus is a product-oriented drug delivery company focused on the development of improved pharmaceutical products with less side effects, increased patient compliance and better efficacy. Since our inception in 1995, we have established a successful track record and maintain partnerships with large and small biotech and pharma companies throughout the world.
   
   Our business activities include formulation development services, drug delivery technologies and controlled release product development. Please use the menu to learn more about our activities.
   
   Today at 4 PM CET: web seminar on protein therapeutics and drug delivery solutions for immunogenicity issues. Go to our web seminars page to join in!
   
3. [verwijderd] 23 oktober 2009 07:04

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Thursday 22 October at 16hr CET
   
   op de seminars page... lol
   
   was al oud hoor, maar staat nog steed TODAY op.
4. flosz 28 april 2010 12:57

   auteur info

   •    flosz

     Lid sinds: 13 feb 2008

     Laatste bezoek: 01 jul 2024

   •    Aanbevelingen

     Ontvangen: 5298

     Gegeven: 2795

   •    Aantal posts: 7.005

   quote:

   de echte zoef schreef:

   Web seminar June 2009: Liposomes for drug delivery
   Web seminar October 2009: Hydrogels for controlled delivery of protein therapeutics
   

   Even geleden, steeds interessant.
   Linkjes erbij.
   
   WEB SEMINAR ON LIPOSOMES
   Web seminar on liposomes for drug delivery
   This web seminar took place on 4 June 2009.
   
   Liposomes for drug delivery: what, why and how?
   Why you should participate:
   - Gain insight into the benefits of liposome drug delivery and the technical challenges of liposome formulation and production
   - Hear about the experience in this area from speakers from Utrecht University and OctoPlus
   - Join an interactive webinar that leaves ample opportunity to discuss your experience or questions regarding liposomal drug delivery
   
   Speakers include:
   Prof. Daan Crommelin, Utrecht University
   Professor Crommelin is professor at the Department of Pharmaceutics at Utrecht University. He is adjunct professor at the Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. Prof. Crommelin published extensively and is on the editorial board of 10 peer reviewed journals in the pharmaceutical sciences.
   
   What you can learn:
   Liposomes are versatile carriers of a wide array of active molecules. By tailoring their pharmacokinetics, reducing toxicity, targeting to specific organs or lesions, liposomes can accommodate virtually any drug delivery strategy.
   
   Selection of lipids, a suitable processing method, up-scaling of liposomal formulations and manufacture at a commercial scale must be dealt with before liposomal formulations can become a viable product. The scaling up of a bench scale preparation method to an industrial production process is a challenging task, but can be done successfully when specific expertise and appropriate equipment are available. These aspects will be discussed during the webinar and there will be ample opportunity to discuss your experience or questions regarding liposome formulations.
   www.octoplus.nl/gfx/OCTOPLUS_podcast1...
   WEB SEMINAR ON HYDROGELS FOR CONTROLLED DELIVERY OF PROTEINS
   Therapeutic proteins – the immunogenicity challenge
   This web seminar took place on Thursday 22 October at 16hr CET
   What you can learn during this web seminar:
   • Learn about common immunogenicity issues of therapeutic proteins and the impact of formulation on immunogenicity, including the use of hydrogels
   • Gain insight into the benefits of hydrogel microspheres for sustained release of proteins and the technical challenges of microsphere formulation and production
   • Hear about the experience in this area from speakers from Utrecht University and from OctoPlus
   • Join this interactive webinar that leaves ample opportunity to discuss your experience or ask questions regarding protein immunogenicity and drug delivery strategies to solve immunogenicity issues.
   Therapeutic protein products need to be as free from aggregates as possible to reduce the risk of immunogenicity. One solution is to use a controlled release formulation in which the compound is encapsulated in microspheres. The choice of microsphere matrix and the way of formulating and manufacturing determine the success of an aggregate-free drug product. The distinction between antigenicity and "tolerance breaking" will be explained as well as the relationship to the purity of the protein drug substance. These aspects will be discussed during the webinar and there will be ample opportunity to discuss your experience and ask your questions.
   
   Speakers:
   
   Prof. Huub Schellekens, Pharmaceutical Biotechnology, Utrecht University, Netherlands.
   Dr. Huub Schellekens teaches Medical Biotechnology at the Department of Innovation Studies at Utrecht University and has a research position at the Faculty of Pharmaceutical Sciences. He is a member of the Board of the European Immunogenicity Platform, member of the Dutch Medicine Evaluation Board and National Expert of the European Medicine Evaluation Agency. He published more than 300 papers in peer reviewed international journals concerning many aspects of the development of therapeutic proteins, such as immunogenicity of protein drugs and issues concerning biosimilars.
   
   Ruud Verrijk, Ph.D., Principal Scientist, OctoPlus N.V.
   Ruud Verrijk has over 20 years of experience in the design and analysis of drug delivery systems obtained in positions at the Netherlands Cancer Institute, Solvay Pharmaceuticals, and OctoPlus. He has published in peer reviewed journals on delivery systems, pharmaceutical analysis, drug formulation and pharmacology, and is inventor on many patents in this field.
   www.octoplus.nl/gfx/podcast2.mp4
   ***********************
   Vandaag:
   
   Controlled Release
   28th to 29th April 2010, Crowne Plaza Hotel - St James, London, United Kingdom.
   
   28-04-2010
   
   3.50 Design and clinical manufacture of controlled release biopharmaceuticals
   • Types of controlled release formulations and release profiles
   • Critical parameters in the process development of controlled release biopharmaceuticals
   • Clinical results to date: Phase II clinical data of a controlled release formulation of interferon alfa
   
   Gerben Moolhuizen, Chief Business Officer, OctoPlus
   www.smi-online.co.uk/events/programme...
   
   
5. [verwijderd] 28 april 2010 15:00

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Heel mooi die berichten hier plaatsen, maar die koers daalt er alleen maar van.
6. [verwijderd] 29 april 2010 06:35

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   hepatitiscnewdrugs.blogspot.com/2010/...
7. [verwijderd] 4 mei 2010 16:49

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Het aandeel blijft mooi liggen an laat zich niet meeslepen met het sentiment......